Arcus Biosciences, Inc.
RCUS· NYSE
Released Feb 25, 2026, after the close
10-K filed Feb 25, 2026, 56 days after period end · 0001724521-26-000009
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Revenue | $225.00M | $230.00M | $31.00M | — |
| Net Income | -$106.00M |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$94.00M |
| -$81.00M |
| -$67.00M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.